GlassScriptPhysician profile
Abigail Lyn Ware
NPI 1831899210
$3,749.54
in general payments reported to CMS, 2019-2025
26 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,016 · 2024: $1,445 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,749.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.48 | 2023-2025 | |
| Novo Nordisk INC | $507.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $489.61 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $363.35 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $172.99 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.34 | 2023-2025 | Jardiance, Tradjenta |
| Axsome Therapeutics, INC. | $129.52 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $112.68 | 2024 | Trelegy Ellipta, Arexvy |
| Tolmar, INC. | $111.61 | 2023-2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.15 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $91.45 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.09 | 2023-2025 | Caplyta |
| Astellas Pharma US INC | $79.46 | 2023-2025 | Veozah |
| Corium, LLC | $69.46 | 2023-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $66.73 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.85 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $43.48 | 2023-2024 | Nexletol |
| Lundbeck LLC | $41.38 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $29.49 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $28.43 | 2023 | Krystexxa |
| Inspire Medical Systems, INC. | $19.17 | 2024 | Inspire |
| Neos Therapeutics, LP | $17.33 | 2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $16.46 | 2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2023 | Livalo |
| Xeris Pharmaceuticals, INC. | $15.10 | 2025 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $13.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.